Home / Health / FDA Greenlights Novel CAR-T for Autoimmune Diseases
FDA Greenlights Novel CAR-T for Autoimmune Diseases
10 Jun
Summary
- FDA cleared CTA313, a dual-targeted CAR-T therapy.
- Trial will assess CTA313 in lupus and multiple sclerosis patients.
- Off-the-shelf therapy offers faster treatment potential for patients.
The U.S. Food and Drug Administration has cleared Imviva Biotech's Investigational New Drug application for CTA313, a novel dual-targeted CAR-T therapy. This groundbreaking treatment is designed to combat B-cell-mediated autoimmune diseases.
The therapy will be assessed in a Phase 1b clinical trial. This trial will focus on patients diagnosed with systemic lupus erythematosus, progressive multiple sclerosis, and autoimmune encephalitis, among other autoimmune conditions.
Imviva Biotech emphasized a key advantage of CTA313: its allogeneic, 'off-the-shelf' manufacturing process. This allows the therapy to be produced in advance, making it readily available and potentially enabling eligible patients to begin treatment sooner.
